Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis

Thorax

Volumn 73, Issue 10, 2018, Pages 918-925

  Pinder, Emma M ^a   Rostron, Anthony J ^a   Hellyer, Thomas P ^a   Ruchaud Sparagano, Marie Helene ^a   Scott, Jonathan ^a   MacFarlane, James G ^a   Wiscombe, Sarah ^a   Widdrington, John D ^a   Roy, Alistair I ^b   Linnett, Vanessa C ^c   Baudouin, Simon V ^d   Wright, Stephen E ^e   Chadwick, Thomas ^a   Fouweather, Tony ^a   Juss, Jatinder K ^f   Chilvers, Edwin R ^f   Bowett, Susan A ^g   Parker, Jennie ^g   McAuley, Daniel F ^h   Conway Morris, Andrew ^f   Simpson, A John ^a   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

bacterial infection; gm csf; neutrophil biology

Indexed keywords

HLA DR ANTIGEN; PLACEBO; SARGRAMOSTIM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ALL CAUSE MORTALITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG SAFETY; FEVER; FOLLOW UP; HOSPITAL INFECTION; HUMAN; HYPERTRANSAMINASEMIA; INFECTION RISK; INTENSIVE CARE UNIT; INTESTINE OBSTRUCTION; MONOCYTE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL; PNEUMOMEDIASTINUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; THROMBOCYTOSIS; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PHAGOCYTOSIS; TREATMENT OUTCOME;

EID: 85050927510     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2017-211323     Document Type: Article

References (36)

1. Fagon JY, Novara A, Stephan F, et al. Mortality attributable to nosocomial infections in the ICU. Infect Control Hosp Epidemiol 1994;15:428-34.
2. Ylipalosaari P, Ala-Kokko TI, Laurila J, et al. Intensive care acquired infection is an independent risk factor for hospital mortality: A prospective cohort study. Crit Care 2006;10:R66.
3. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-208.
4. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9.
5. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011;1:47.
6. Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: An observational, multicentre cohort study. Lancet Infect Dis 2011;11:181-9.
7. Hranjec T, Rosenberger LH, Swenson B, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensivecare-unit-acquired infection: A quasi-experimental, before and after observational cohort study. Lancet Infect Dis 2012;12:774-80.
8. Hughes JM. Preserving the lifesaving power of antimicrobial agents. JAMA 2011;305:1027-8.
9. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013;13:159-75.
10. Amulic B, Cazalet C, Hayes GL, et al. Neutrophil function: From mechanisms to disease. Annu Rev Immunol 2012;30:459-89.
11. Morris AC, Brittan M, Wilkinson TS, et al. C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. Blood 2011;117:5178-88.
12. Conway Morris A, Kefala K, Wilkinson TS, et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 2009;180:19-28.
13. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colonystimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med 2009;180:640-8.
14. Orozco H, Arch J, Medina-Franco H, et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006;141:150-3.
15. Rosenbloom AJ, Linden PK, Dorrance A, et al. Effect of granulocyte-monocyte colonystimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005;127:2139-50.
16. Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial of granulocytemacrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002;166:138-43.
17. Schefold JC, Zeden JP, Pschowski R, et al. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2, 3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand J Infect Dis 2010;42:164-71.
18. Prescott HC, Calfee CS, Thompson BT, et al. Toward smarter lumping and smarter splitting: Rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 2016;194:147-55.
19. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
20. Dransfield I, Buckle AM, Savill JS, et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol 1994;153:1254-63.
21. Ruchaud-Sparagano MH, Drost EM, Donnelly SC, et al. Potential pro-inflammatory effects of soluble E-selectin upon neutrophil function. Eur J Immunol 1998;28:80-9.
22. Ruchaud-Sparagano MH, Walker TR, Rossi AG, et al. Soluble E-selectin acts in synergy with platelet-activating factor to activate neutrophil beta 2-integrins. Role of tyrosine kinases and Ca2+ mobilization. J Biol Chem 2000;275:15758-64.
23. Koopman G, Reutelingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
24. Conway Morris A, Anderson N, Brittan M, et al. Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients. Br J Anaesth 2013;111:778-87.
25. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001;286:1754-8.
26. Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32:1175-83.
27. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997;3:678-81.
28. Landelle C, Lepape A, Voirin N, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 2010;36:1859-66.
29. Conway Morris A, Datta D, Shankar-Hari M, et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med 2018;44:627-35.
30. Cebon JS, Bury RW, Lieschke GJ, et al. The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. Eur J Cancer 1990;26:1064-9.
31. Hovgaard D, Mortensen BT, Schifter S, et al. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993;50:32-6.
32. Brach MA, deVos S, Gruss HJ, et al. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 1992;80:2920-4.
33. Yong KL, Linch DC. Granulocyte-macrophage-colony-stimulating factor differentially regulates neutrophil migration across IL-1-activated and nonactivated human endothelium. J Immunol 1993;150:2449-56.
34. Summers C, Singh NR, White JF, et al. Pulmonary retention of primed neutrophils: A novel protective host response, which is impaired in the acute respiratory distress syndrome. Thorax 2014;69:623-9.
35. Paine R 3rd, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human GM-CSF for patients with acute lung injury. Crit Care Med 2012;40:90-7.
36. Matute-Bello G, Liles WC, Radella F 2nd, et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med 2000;28:1-7.